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Brain metastasis, an important cause of cancer morbidity and mortality, occurs in at least 30% of patients with breast cancer. A
key event of brain metastasis is the migration of cancer cells through the blood-brain barrier (BBB). Although preventing brain
metastasis is immensely important for survival, very little is known about the early stage of transmigration and the molecular
mechanisms of breast tumor cells penetrating the BBB. The brain endothelium plays an important role in brain metastasis,
although the mechanisms are not clear. Brain Microvascular Endothelial Cells (BMECs) are the major cellular constituent of
the BBB. BMECs are joined together by intercellular tight junctions (TJs) that are responsible for acquisition of highly selective
permeability. Failure of the BBB is a critical event in the development and progression of several diseases that affect the CNS,
including brain tumor metastasis development. Here, we have delineated the mechanisms of BBB impairment and breast cancer
metastasis to the brain. Understanding the molecular mediators that cause changes in the BBB should lead to better strategies for
effective treatment modalities targeted to inhibition of brain tumors.
1. Introduction
Breast cancer patients often develop metastatic lesions in
the brain [1, 2]. The development of CNS metastasis in
patients with solid malignancies represents a turning point in
the disease process. The prevalence of CNS metastasis from
breast cancer may be increasing due to improved systemic
therapy for stage IV breast cancer. The standard treatment
for multiple brain lesions remains whole-brain radiation for
symptom control, with no improvement in survival. The
therapy for a single brain metastasis remains either surgery or
radiosurgery, with conflicting information as to the benefit of
prior whole-brain radiation.
To metastasize to the brain, breast cancer cells must
attach to microvessel endothelial cells and then invade the
blood-brain barrier (BBB), which constitutes the endothe-
lium and the surrounding cells. The BBB is a unique
anatomical structure that is mainly defined by tight junctions
and adherens junctions between the brain endothelial cells,
that strictly regulate the flow of ions, nutrients, and cells into
the brain [3, 4]. Compared with endothelial cells from other
vascular beds, brain microvascular endothelial cells (BMECs)
characteristically have very low permeability to solutes, high
electrical resistance, complex tight junctions, and an array of
transport systems that both supply the brain with nutrients
and eliminates byproducts of brain metabolism. The low
permeability is also important in protecting the brain from
toxins circulating in the blood and restricting the migration
of leukocytes and monocytes. The BMECs form an active
permeability barrier and transport system known as the BBB,
which is instrumental in the control of the brain fluid milieu.
A widely supported hypothesis is that tumor cell adhesion to
endothelium induces a retraction of the endothelium, which
exposes the vascular basement membrane to the tumor cells.
Numerous studies have shown that tumor cells recognize
and bind to components in the vascular membrane, thereby
2 Pathology Research International
initiating extravasation and the beginning of new growth
at secondary organ sites. The impairment of the BBB was
observed recently in breast cancer patients who developed
metastasis to the brain [5].
The BBB, a regulated interface between the periph-
eral circulation and the central nervous system (CNS),
is comprised of the cerebral microvascular endothelium,
which together with neurons, astrocytes, pericytes, and
the extracellular matrix, constitute a “neurovascular unit”
(Figure 1) [3, 4, 6]. The BBB is a highly selective diffusion
barrier at the level of the cerebral microvascular endothe-
lium, characterized by the presence of mainly tight cell-
cell junctions, adherens junctions and lack of fenestrations
(Figure 2). The BBB regulates bidirectional control over the
passage of a large diversity of regulatory proteins, nutrients
and electrolytes, as well as potential neurotoxins [7, 8].
Increased BBB permeability can be either a consequence
of the pathology or a precipitating event [7, 8]. Impairment
of the BBB leads to an increase in permeability and forma-
tion of edema. Inflammatory mediators such as histamine,
bradykinin, and Substance P cause increase in permeability
of BBB in vivo, which results from the rapid formation of
endothelial gaps [7, 8].
2. Tight Junctions and Blood-Brain
Barrier Integrity
Most forms of brain injury are associated with BBB dis-
ruption, resulting in secondary damage to neural cells. The
interendothelial space of the cerebral microvasculature is
characterized by the presence of a junctional complex that
includes adherens junctions (AJs), tight junctions (TJs) and
Gap junctions [8] (see Figure 3). Whereas gap junctions
mediate intercellular communication, both AJs and TJs act
to restrict the permeability across the endothelium. AJs are
ubiquitous in the vasculature and mediate the adhesion of
endothelial cells to each other, contact inhibition during
vascular growth and remodeling, initiation of cell polarity
and partly the regulation of paracellular permeability. The
primary component of AJs is VE-cadherin. The TJs are
the main components that confer the low paracellular
permeability and high electrical resistance. TJs are elaborate
structures that span the apical region of the intercellular
cleft of endothelial barrier tissues. TJs function both as a
“zipper” and a “fence” that limit paracellular permeability
and are composed of transmembrane proteins as primary
seals linked via accessory proteins to the actin cytoskeleton.
The TJs are composed of a complex of belt-like zonula
occludin, which is localized close to the lumen of the
capillary. Electrical resistance in vivo across the barrier can
increase to approximately 1200 ohm·cm2 or higher due to
the TJs. The proteins of the TJs include the junctional
adhesion molecules (JAM) (JAM-1, JAM-2 and JAM-3),
occludin, the claudins, and zonula occludin proteins (ZO-1
and ZO-2). Interestingly, brain microvascular endothelial
cells do not express ZO-3 [8].
The ZO proteins are involved in the coordination and
clustering of protein complexes to the cell membrane
and in the establishment of specialized domains within
the membrane [3]. ZO-1 links transmembrane proteins of
the TJ to the actin cytoskeleton. The primary cytoskeletal
protein, actin, has known binding sites on all ZO proteins
and on claudins and occludin. Actin filaments serve both
structural and dynamic roles in the cell. ZO-1 binds to actin
filaments and to the C-terminus of occludin and claudins,
which couples the structural and dynamic properties of
perijunctional actin to the paracellular barrier.
The numerous pathways by which specific TJ proteins are
regulated and the specific effects of certain pathologies on
tight junction (TJ) proteins strongly suggest that therapies
targeted to components of the TJ complex and its modulators
for the treatment and prevention of breast metastasis to the
brain and development of brain tumors are a promising
avenue that needs to be explored.
3. Genes That Mediate Breast Cancer
Metastasis to the Brain
The molecular mediators that influence metastasis in distant
sites appear to vary by organ (Figure 4). In malignancies of
the breast, cancer cells enter a prolonged period of latency
before they gain competence to colonize and produce organ-
specific metastases [10–12]. During this period of time, dis-
seminated cancer cells may acquire distinct sets of metastasis
functions depending on the target organ [13, 14]. Despite the
various infiltration and colonization functions, the general
process of metastasis can be broken down into local invasion,
intravasation, survival in the circulation, extravasation and
colonization [15] (Figure 5). After intravasation the cancer
cells need to survive in the circulation, travel to specific target
organs and extravasate into a microenvironment where they
can colonize as secondary tumors [15]. Searches for genetic
determinants of metastasis have led to identification of
gene signatures that selectively mediate breast cancer cell
metastasis to bones, the lungs, and the brain [13–15]. Based
on previous work on genomic analysis of breast cancer
metastasis to bone and lung, the Massague´ group identified
three tumor metastasis genes that mediate extravasation
through the BBB and cancer cell colonization in the brain
[15]. The barriers to metastasis are distinct in organs. To
colonize the brain parenchyma, invading tumor cells must
penetrate the blood-brain barrier (BBB). Brain capillary
walls are more difficult to penetrate due to a tight layer
of endothelial cells, tight junctions, and astrocyte foot
processes [10, 16]. Functional validation of these genes
provided clues as to how cancer cells can penetrate the
BBB and initiate tumor growth in brain vasculature. A
brain metastasis signature (BrMS) consisting of 17 genes was
created using genomic profiling and univariate analysis. The
cycloxygenase-2 (COX2), the epidermal growth factor recep-
tor (EGFR) ligand HB-EGF, and the α2, 6-sialyltransferase
(ST6GALNAC5) were identified as mediators in cancer
cell extravasation and infiltration through the BBB. The
expression of COX-2 and EGFR ligand HB-EGF enhances
the extravasation of cancer cells across the capillaries in an
in vivo animal model system. The ST6GALNAC5 expression
is restricted to the brain both in mice and humans [17].
The knockdown of ST6GALNAC5 reduced the cell passage
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Figure 2: Schematic Presentation of TJs Structures in BMECs [9].
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Figure 4: Cancer metastasis. Pathogenesis of cancer metastasis: the process of cancer metastasis consists of sequential, interlinked, and
selective steps. The outcome of each step is influenced by the interaction of metastatic cells with homeostatic factors. Each step of the
metastatic process is considered rate limiting in that failure of a tumor cell to complete any step effectively terminates the process. Therefore,
the formation of clinically relevant metastases represents the survival and growth of unique subpopulations of cells that preexist in primary
tumors.
Pathology Research International 5
Tumor cells
VEGF
VEGF
1- Activation
2- Adhesion 3- Extravasation
Astrocytes
Brain microvascular
endothelial cells
(BMECs)
Figure 5: Schematic presentation of tumor cell penetration across the BBB.
through a BBB and suppressed metastasis to the brain. In an
in vitro model of BBB, which consisted of human primary
endothelial cells and astrocytes, Massague´ and colleagues
demonstrated that the ST6GALNAC5 can increase cancer cell
adhesion to brain endothelial cells and infiltration through
the BBB. The Massague´ group has previously identified
four lung metastasis gene signature (LMS) that contribute
to vascular remodling of tumor blood vessels, entry into
the circulation and passage into the lung parenchyma [13].
Comparison of the BrMS with the lung metastasis signature
(LMS) showed an overlap of genes between signatures, but
not in the bones or liver. Some of the overlapped genes
include COX-2, EGFR ligand, ANGPTL4, and LTBP1, which
are known to promote disruption of the endothelial barrier
and metastasis to the brain and lung. The Massague´ group
suggested that these genes may specifically contribute to
expression signatures that are predictive of metastasis in the
brain.
4. Cooption of Tumor Cells with
Brain Endothelium
Given the observations that certain cancers may have
preferential metastatic sites it is natural to investigate what
factors, if any, make the brain an “attractive” target for tumor
cell growth; specifically in regards to breast primary tumors.
The widely accepted “seed and soil” hypothesis first offered
by Piaget in 1889 has been credited as the most plausible
explanation for the targeted behavior seen in the progression
of cancer growths [18]. If accepted, it follows that brain tissue
(the “soil”) consisting of neurons, extensive vasculature, and
associated neuropil have trophic effects that attract breast
primary tumor cells (the “seed”) and facilitate their growth.
To deduce the validity of this, still prevalent, century-old
hypothesis it is vital to observe metastasis before, during,
and immediately following successful “colonization” of the
distant site. It is within this time frame that any mechanisms,
such as Paget’s proposal of trophic factors, may play a
central role. The time point of interest, referencing current
knowledge of metastatic progression, lies in the events
between extravasation into distant tissue and any subsequent
neoangiogenesis-driven growth (Figure 4) [19].
It is important to emphasize at this time that the
current discussion will focus on the breast-brain relation-
ship. The genetic heterogeneity of migrating tumor cells is
well documented and undoubtedly contributes to profound
differences in interaction involving other tissues and organs
[20, 21]. Carbonell and colleagues are equally cautious of
this distinction, especially in light of their data and its
contradiction to the Piagetian “soil” concept. In their paper
they reference the relative lack of direct evidence for Paget’s
hypothesis based on in vivo studies [22]. It is this lack of
convincing proof that prompted the study of breast cancer
cell migration to the brain with a greater focus on the specific
steps that lead to successful colonization.
In their paper, direct observation of early tumor colo-
nization revealed a predisposition for growth around existing
brain vasculature. This vascular “cooption” contradicts the
notion proposed by Paget that trophic factors from dis-
tant tissue are responsible for the initial establishment of
migrating tumor cells. This is not to deny the possibility that
cytokines and chemokines are responsible for drawing tumor
cells to certain areas as they traverse the systemic circulation.
The possibility of chemoattraction via the CCR7 and CXCR4
receptors has been shown and recognized [23]. Upon arrival,
tumor cells preferentially attach to existing blood vessels [22]
rather than the chemoattractant releasing neural tissue as
expected from the Piagetian viewpoint. Thus, from current
knowledge it can be inferred that trophic signaling could
play a role in the macroscopic targeting of breast primary
tumor cells to the brain, but that the same factors may have a
diminished role once access to brain tissue has been attained.
They based their initial experiments on the behavior of
the MDA-MB-231 cell line. Interestingly, they conducted
identical tests with the “brain seeking” MDA231BR cell line
as well as A7 (human melanoma) and K1735M2 (murine
melanoma) cell lines. All cell lines tested exhibited behaviors
consistent with vascular cooption.
The underlying similarity between all conditions and
tests is the brain host tissue, its vascular basement membrane
and HBMECs. The tight junctions and associated pericytes
of the blood brain barrier are a difficult challenge for any
invader to penetrate. This includes “invasion” by researchers
and clinicians attempting to deliver chemotherapeutic agents
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and other drugs [24]. The slower rate of extravasation
in brain is well noted in comparison to the fenestrated
capillaries of other tissues such as bone and liver [25].
It is this unique property of brain microvasculature, a
tightly regulated series of junctional complexes that may
explain the “antiPiagetian” findings described above. The
question becomes whether or not this difficulty in extrava-
sation directly promotes the viability of vascular cooption
over direct attachment and growth on neural tissue. It is
important to note that these recent findings on vascular
cooption within the brain do not diminish the substantial
effect of neoangiogenesis on subsequent growth in tumor
size and scope. It has been shown that lack of new blood
vessel formation and/or remodeling often leads to the death
or incapacitation of tumorigenic tissue [26]. Successful
migration and initial attachment are steps that must be
conceptually separated from the unregulated macroscopic
growth that commonly defines cancer. Thus, vascular coop-
tion [22] is the most reliable method by which breast primary
tumor cells are able to procure the necessary nutrients
and physical scaffolding for initial implantation and growth
within the brain.
5. Colonization of Tumor Cells around
the Blood Vessels
The importance of vascular cooption as a means for
tumor cells to survive is highlighted in a study by Gevertz
and Torquato [27]. They explain that neoplastic growth
is possible even with angiogenesis inhibited as long as
vascular cooption is an alternative [27]. Nonetheless, they
also report that neoangiogenesis and vascular remodeling
is necessary if tumor masses are to grow beyond 1-2mm
in diameter. As aforementioned migration and early attach-
ment/colonization should be considered separate from the
macroscopic growth step. Clearly, it is the proximity to, as
well as early and ongoing interaction with blood vessels
in the brain, that contributes significantly to tumor cell
fate.
The focus of Gevertz and Torquato on the effects of
VEGF, Ang-1, and Ang-2 are interesting in their interplay.
They find a pattern of vascular cooption, vessel regression,
and robust angiogenesis that requires tight regulation of
these factors [27]. The possibility of regulation at the gene
level warrants further study. Such a mechanism supports
data on the genetic heterogeneity of primary tumor cells
and the Darwinian selection of those tumor cells with the
capability for metastasis [28].
It is known that primary tumors can shed more than a
million cells per gram of the tumor mass a day [19]. Despite
this constant dispersal of tumor cells, and despite public fear
and opinion, metastasis is relatively difficult and inefficient.
Thus, the study of physiological changes due to changes at
the gene level is a promising direction for cancer research.
In light of the importance of vascular cooption and blood
vessel colonization to invading tumor cells, a look at gene-
regulated factors influencing vascular cooption and coloniza-
tion could provide a clue to the prevention of secondary
growths.
angiogenesis, as we have discussed, is a late event when
considering first the chemotaxis of tumor cells, extravasation
past the blood brain barrier, and finally successful vascular
cooption. The steps preceding angiogenesis, according to
Lorger and Felding-Habermann contribute to the lower
success rate of brain metastasis compared with other tissues
[25]. They report that tumor cells extravasating into brain
parenchyma were found to be arrested in G0 of the cell
cycle. These findings suggest an amount of stress and
energy expenditure consistent with a greater effort needed
in penetrating the intercellular junctions already discussed
in this paper. It is well known that loss of cell attachment
proteins and mechanisms leads to the shedding of material
from primary tumors [20]. The loss of function in E-
cadherin through the disruption of alpha-catenin and/or
beta-catenin is well known [1]. We have revealed here that
the process for metastasis could very well complete the
circle, at least in regards to breast-brain metastasis. Just as
loss of adhesion is a necessary first step for tumor cells
to leave their primary tissue site, prompt adhesion to the
vascular basement membrane of brain endothelial cells is
required (and sufficient) for initiation of secondary growth.
From evidence collected thus far, it is a possibility that
attachment proteins and their constituents largely assume
control of primary tumor cell fate as soon as extravasation
into brain tissue is complete; wresting control away from
any trophic factors. There is evidence that the presence of
the blood brain barrier would make such a shift in cellular
interaction necessary. Regardless, early colonization around
the brain’s existing vasculature appears to be necessary for
successful metastasis and has the potential for future clinical
therapies aimed at prevention of secondary growths within
the brain.
6. Reactive Astrocytes and Glia on
Tumor Growth
The brain provides a unique microenvironment due to its
distinctive structure of extracellular matrix (Table 1) and the
blood brain barrier (BBB) [29]. It is known that interactions
of the host microenvironment and metastatic cells affect
the outcome of metastatic progression and tumor survival
[30]. Lorger and Felding-Habermann provided in depth in
vivo analyses of early changes in brain microenvironment
upon arrival of breast cancer cells [31]. For studies of
the breast cancer cell arrest and extravasation into the
brain parenchyma, the Habermann group established breast
cancer cell models using MDA-MB-231/brain cells, MDA-
MB-435 and murine 4T1 cancer cells. After cell injec-
tion into left carotid artery of mice, astrocyte activation
was detected in the left hemisphere in brain, showing
consistent upregulation in the vicinity of intravascular
arrested cancer cells. Reactive astrocytes surrounded and
infiltrated brain metastases. Consistent astrocyte activation
was detected throughout the extravasation process as well
as upregulation of matrix metalloproteinase-9 (MMP-9)
proteins in close proximity of extravasating cancer cells.
The astrocytic MMP-9 factor can influence cancer cell
invasion by promoting growth and angiogenesis in primary
Pathology Research International 7
Table 1
ECM molecules Candidate or demonstrated receptors Collagen
Integrins (a1fl1, a2fl1, a3/.3), CD44,
syndecan, proteoglycans
Laminins
Integrins (a13, a2fl, a3f3, a6fl, and a7j3;
avjIs, a6fl4), dystroglycan,
lactose-binding lectins, proteoglycans
Thrombospondins
Integrins avfls, avj3x, axfij, CD36,
syndecan, proteoglycans, sulfatides
Tenascin
Fl 1, integrins (axflj) syndecan, cytotactin
binding proteoglycans
Fibronectin
Integrins (av/33, avf36, asfli, a5fl), CD44,
syndecan, proteoglycans
Proteoglycans Hyaluronan, integrins
brain tumors through release of vascular endothelial growth
factors (VEGFs) from the extracellular matrix [32]. In
addition to angiogenesis, VEGF also has the function to
support the survival and dissemination of breast carci-
noma cells [33]. Habermann and Lorger suggested that
early involvement of reactive astrocytes may influence the
tumor cell fate within the brain parenchyma. In their
study, some reactive astrocytes expressed nestin during
early cancer cell invasion. In melanoma cells, astrocytes
secret haparanase to support the brain microenvironment
and the growth of metastatic cells [34], in addition to
astrocytes, microglia responses to invading breast cancer
cells were detected. Unlike astrocytes, microglia activation
associated with the cancer cell brain colonization was not
consistent. The active and reactive microglial populations
displayed different phagocytic activities and morphology.
Despite the differences, a variety of glial responses adds
uniqueness to local brain microenvironment of which is
essential in determining tumor cell invasion and pro-
gression. Astrocytes may have multiple functions in the
brain microenvironment. In response to brain injury, astro-
cytes are activated and recruited to form a glial scar
in the site of injury [33]. They can protect neurons
from injury induced apoptosis [35]. The Fidler group
determined whether reactive astrocytes can also provide
neuroprotective properties on protecting tumor cells from
cytotoxicity induced by chemotherapeutic drugs. In vitro
study demonstrated that activated astrocytes protect tumor
cells from chemotherapeutic drugs through direct physical
contacts.
Astrocytes play important roles in maintaining home-
ostasis in the brain by regulating nutrient transport, ion
trafficking across the extracellular matrix (Table 1) as well
as neuronal signaling. It has been shown that specific
interactions between brain endothelium and astrocytes
within neurovascular units (Figure 1) can influence BBB
permeability under pathological conditions. Interactions
between the brain endothelium, astrocytes, and neurons
may also regulate blood-brain barrier (BBB) function [36].
Cancer cell progression and survival depend on interplay
between local host cells and invading tumor cells. Although
the specific functions of astrocytes and microglia in early
metastatic invasion are yet to be determined, studying local
host cells responses during tumor cells invasion may lead
to better understanding of tumor microenvironment. Such
information could lead to a new avenue of therapeutic targets
for brain metastases.
7. Angiogenesis and Brain Tumor Growth
New blood vessel formation plays an important role in breast
cancer growth, invasion, and metastasis. Tumor growth is
preceded by the development of new blood vessels, which
provide a pathway for metastasis and nutrients essential for
growth. Vascular endothelial growth factor A (VEGF) is
a key angiogenic mediator that stimulates endothelial cell
proliferation and regulates vascular permeability [37, 38].
Highly proliferative tumors, such as those that are negative
for the estrogen, progesterone, and Her2/neu receptors have
enhanced angiogenesis that supports rapid growth and early
metastasis; also expressing high levels of VEGF [39]. Thus,
breast cancer patients that have tumor cells secreting high
levels of VEGF may have a higher risk of developing breast
cancer metastasis to the brain. VEGF also acts in concert
with Angiopoietin2 to regulate vessel growth. In human
cancers, increased expression of Ang2 in tumor cells is
closely correlated to tumor cell progression, invasiveness, and
metastasis [40, 41].
VEGF is essential for angiogenesis and BBB function-
ing. Our previous studies showed that VEGF upregulated
ICAM-1 via phosphatidylinositol 3 OH-kinase/AKT/Nitric
oxide pathway and modulated migration of HBMECs [42].
Using human cytokine cDNA array, we found that VEGF-
induced significant increase in expression of monocyte
chemoattractant protein-1, the chemokine receptor CXCR4
as well as IL-8 in HBMECs [43]. VEGF increased IL-8 pro-
duction in HBMECs through activation of nuclear factor-κB
via calcium and phosphatidylinositol 3-kinase pathways [44].
We also showed that VEGF secreted from breast cancer cells
significantly increased the adhesion and penetration of breast
cancer cells across the HBMECs monolayer, via changes of
VE-cadherin which were inhibited by SU-1498 inhibitor for
VEGFR-2 and calcium chelator. VEGF also regulated focal
adhesion assembly in HBMECs through activation of FAK
and RAFTK/Pyk2 [45]. These focal adhesions are complexes
comprised of scaffolding and signaling proteins organized by
adhesion to the extracellular matrix (ECM). Further, VEGF
upregulated the expression of α6 integrin and increased the
α6β1 integrin expression in HBMECs which were important
for VEGF induced adhesion and migration as well as in vivo
angiogenesis and tumor angiogenesis [46].
VEGF and its cognate receptors are central to the regula-
tion of angiogenesis in both physiological and pathological
states. In cancer, local tumor hypoxia stimulates VEGF
synthesis and VEGF levels are subsequently elevated in
8 Pathology Research International
breast cancer. VEGF expression levels correlates with poor
prognosis. Blocking of the VEGF-VEGF receptors pathway is
accepted as the first antiangiogenic therapy. However, since
tumors often develop evasive resistance to this therapy, the
development of new antiangiogenic approaches is required
for successful antiangiogenic therapy. This can be achieved
by better understanding of the receptors and pathways
involved in vascular remodeling in brain. Angiopoietins and
Tie2 receptor complex were shown to play a critical role
in tumor angiogenesis; however their roles in brain BMECs
remain elusive.
VEGF is the most important factor in the regulation
of the development and differentiation of the vascular
system. By acting as a capillary permeability enhancing agent,
VEGF also affects the integrity of the BBB. As primary
partners of VEGF, angiopoietins (Angs) also play a multiple
critical role in vascular development. Angiopoietins are
ligands for the Tie 2 receptors and have either agonistic
(Ang-1 or Ang-4) or antagonistic (Ang2 and Ang-3) actions
regulating vascular survival and expansion. Ang2 is a natural
antagonist of Angiogenesis in different microenvironments.
Concerted expression of VEGF and Ang2 resulted in
increased microvessel density in solid tumors [40]. Ang2 also
upregulated MMP-1 and MMP-9 in the presence of VEGF
in vitro and MMP elaboration, which participates in the
induction of microvessel sprouting in the growing vascular
network.
8. Clinical Aspects of Breast Cancer
Metastasis to the Brain
Brain metastasis, is a significant cause of morbidity and
mortality in patients with breast cancer. HER-2 positivity
is an increasing recognized risk factor for the development
of brain metastasis [47]. Other than Her2 overexpression,
there are other factors that increase the risk for breast
cancer metastasis to the brain such as negative estrogen
and progesterone receptor status, young age, large tumor
size, elevated Lactate dehydrogenase (LDH), grading, and
number of positive lymph nodes [48].
As breast cancer is the second most common cause of
brain metastasis (after lung cancer) occurring in 10–15%
of patients with breast cancer, autopsy studies suggest that
the actual incidence is twice (∼20 to ∼30%) [47]. The
incidence of brain metastases is thought to be increasing due
to the introduction of more sensitive and accurate diagnostic
methods and screening techniques. During the last decade,
improved adjuvant and palliative therapy regimens have led
to improvement in survival of these patients. In a majority
of these patients, the central nervous system dissemination
occurs several years (∼5 to ∼20 years) after systemic lesions
have been diagnosed. Approximately 70–80% of the lesions
are not solitary but multiple. Cerebrum is the most common
site for breast cancer metastasis, following the cerebellum
and brainstem [48].
Clinically, this parenchymal brain metastasis have an
insidious onset with headache (24–48%), neurological
deficits as focal motor weakness (16–40%), altered men-
tal status and cognitive dysfunction (24–34%). Seizures,
ataxia, nausea, vomiting can also be presenting symptoms.
Leptomeningeal metastasis is presented with nonlocalizing
symptoms such as headache, nuchal rigidity or cranial
neuropathies.
Brain metastasis can be diagnosed through various tech-
niques. Gadolinium-enhanced magnetic resonance imaging
(MRI) is more sensitive than contrast enhanced computed
tomography (CT) for identifying both Parenchymal and
leptomeningeal disease and is therefore preferred method
for detection of brain tumors. Contagious thin axial slices
without skips are necessary to pick up small lesions that
are missed on CT, especially, in the front-temporal region
and in the posterior fossa and brainstem. MRI is also
superior in differentiating between solitary and multiple
lesions. Approximately 20% of patients thought to have
single brain metastases on CT actually have multiple lesions
on MRI. Stereotactic brain biopsy must be considered where
diagnosis of metastasis is in doubt, especially in patients with
a typical presentation as it would lead to change in diagnosis
in about 11% of cases. Primary brain tumors, infections,
infarction and radiation necrosis are the likely alternative
possibilities.
Treatment of brain metastasis depends on many factors
as such location, number of metastasis, age of the patient,
performance, status, and localization of extra cerebral lesions
and a prediction of their responses to systemic therapy. On
the basis of all these findings, a clinician can decide to
have either invasive or noninvasive treatments. Historically,
the incidence of clinically appearing CNS metastases in
patients with breast cancer is 10–20%. The median time
from diagnosis of breast cancer to CNS metastases is about
33 months with 5 months median survival time once
diagnosed with cerebral involvement [47]. The majority
of cancer patients who develop metastatic brain disease,
present with multiple lesions, and death are attributed to
uncontrolled metastatic brain disease in approximately 40%
of the patients. Median survival in untreated patients with
CNS involvement is 1 month; in patients administered
with corticosteroids, the survival rate can go to 2 months;
and following CNS radiotherapy it can go to 3–6 months.
Patients with single CNS lesions and limited systemic disease
amenable to surgery or radiotherapy may achieve median
survival in the range of 10–16 months.
As mentioned earlier, the treatments, prognosis, diag-
nostic criteria could be different for two types of metas-
tasis, parenchymal and leptomeningeal. The management
of patients with brain metastasis can be divided into two
groups one for leptomeningeal and other for parenchymal
metastasis. Further, there are two approaches for treatment
one is symptomatic and the other definitive. Corticosteroids
and Anticonvulsants are symptomatic treatments, while
the definitive treatment includes whole-brain radiotherapy
(WBRT), surgical resection, stereotactic radiotherapy (SRS),
whole-brain radiotherapy with radiosensitizers, intracavi-
tary and interstitial brain irradiation, chemotherapy and
Chemoradiotherapy.
8.1. Leptomeningeal Metastasis. Breast cancer metastasis is
the most common cause of metastasis to the leptomeninges,
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especially from a lobular carcinoma [49]. As described
earlier, the symptoms presented are headache, vomiting,
ataxia, lethargy, spinal symptoms, cranial nerve palsies and
very rarely seizures. Definitive diagnosis is by Cerebrospinal
fluid analysis for the presence of malignant cells. Focal
radiotherapy is given to symptomatic and bulky sites. The
treatment of the entire neuraxis can lead to unaccept-
able toxicity, mainly leukoencephalopathy and dementia.
Those, whose extracranial disease is reasonably controlled,
intrathecal chemotherapy can be done through Ommaya
reservoir or via lumbar puncture. The most commonly
used chemotherapeutic drugs are methotrexate, thiotepa and
more recently liposomal cytarabine (Depot Cyt) [50]. The
median survival even after multimodality therapy is only 12
weeks.
8.2. Parenchymal Metastasis. The most common form of
metastasis is thought to be spread via hematogenous
route. The management and prevention of CNS metastasis
in patients whose tumors over express HER-2/neu need
to be reevaluated in the present trastuzumab era, with
special consideration for prophylactic cranial irradiation,
as trastuzumab is known to increase the incidence of
brain metastasis in this group of patients [51–53]. Along
with the effectiveness of stereotactic surgery and newer
radiotherapy techniques, innovations in blood-brain barrier
disruption have expanded the scope of less damaging
systemic therapies in brain cancer including metastases
[54].
8.3. Chemotherapy. The impermeability of BBB to ionized
water soluble compounds >180 Da and the presence of
the P-glycoprotein efflux pump at the luminal surface
of the brain capillaries result in lack of penetration of
the chemotherapeutic drugs. Though breast cancer is a
chemosensitive disease, there is limited data on the use
of chemotherapy for breast cancer metastatic to brain.
Most commonly used are cyclophosphamide-based regi-
men (along with methotrexate, 5FU, prednisolone, etc.),
producing response rates 17–61% and median duration
of response of 7 months [50]. High dose intravenous
methotrexate has resulted in overall response rates of 56%
[55]. Recently, temozolamide is being extensively evaluated
in phase I and II studies, either alone or in combination
with other chemotherapeutic drugs (vinorelbine, cisplatin
and capecitabine), for recurrent and progressive brain metas-
tasis from solid tumors, including breast cancer [56, 57].
Theses studies have shown median survival time of 4–7
months.
8.4. Whole-Brain Radiotherapy Alone. WBRT is the main
stay of treatment for most patients with brain metastasis,
which produces symptomatic relief especially of headache
and seizures in 75–80% of patients. It also improves survival
to about 3–6 months and quality of life and radiological
response in up to 60% of the cases [58]. For breast cancer
patients, which responds better to WBRT and in patients
with longer life expectancy (>6 months), a fraction size of
less than 3 Gy is usually administered. Other side effects are
alopecia, mild skin toxicity, fatigue, nausea, vomiting, and so
forth. Late side effects are urinary incontinence and memory
or cognitive disturbances. Late radiation-induced dementia
is a rare occurrence, in only 1.9–5.1% of the patients
[59].
8.5. Surgical Resection. Improved imaging and localization
techniques have made surgery an accepted treatment option,
particularly in patients with good prognostic factors. There
is no direct evidence comparing WBRT alone versus surgery
alone. Numerous retrospective studies have reported supe-
riority of surgical resection over WBRT alone, but all of
them had inherent selection bias, that is, patients selected
for surgery had good performance status, single metastatic
lesion, young age and so forth. The median survival in this
good prognostic group is approximately 12 months, better
than that for WBRT. Further, it has been estimated that
only 30% of patients with brain metastases are suitable for
surgery.
8.6. Stereotactic Radiotherapy. It involves the delivery of a
single high-dose fraction of external radiation to a targeted
lesion in the brain using multiple cobalt sources (gamma
knife), modified linear accelerator (LINAC) or cyber knife. It
has a potential to achieve high local control and is essentially
used as a substitute for surgical treatment in patients with
lesions less than about 3 cm in diameter. The good aspects of
SRS are lack of discomfort, minimal invasiveness (no surgical
incision), reduced hospitalization time (outpatient basis),
with negligible damage to the surrounding healthy tissues.
This stereotactic radiotherapy is ideal to target for sterotaxy,
being small, spherical, well defined with distinct margins
on contrast enhancement. These characteristics help to
achieve conformal dose distributions with minimal damage
to surrounding tissues. One of its greater advantages is that it
can be targeted to those areas where surgical resection is not
possible.
Whole-brain radiotherapy with radiosensitizers, intra-
cavitary plus interstitial brain irradiations and chemora-
diotherapy are under clinical trial these days and these
approaches look promising for future management of brain
tumor resulting from breast cancer metastasis.
9. Summary
Brain metastasis is a challenging clinical problem and a
leading cause of death from cancer. Disruption of the
blood-brain barrier was observed in triple-negative breast
cancer and basal type breast cancer patients who devel-
oped breast cancer metastasis to the brain. Elucidation
of the signaling pathways and processes that mediate
the early steps of extravasation of breast tumor cells
across brain microvascular endothelial cells should pro-
vide important information on the biology of tumor cell
entry to the brain. Ultimately, this could lead to the
design of better therapeutical approaches for blocking
changes in permeability and integrity of the brain vascu-
lature and inhibiting brain tumor angiogenesis and tumor
growth.
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